All Journals

Advances the science and practice of clinical and medical microbiology. The journal serves microbiologists, infectious disease clinicians, laboratory scientists and public health researchers with rigorous, original scholarship that bridges the diagnostic laboratory and the bedside. We welcome original research, reviews, case reports and editorials across antimicrobial resistance (AMR) and antimicrobial stewardship, diagnostic and molecular microbiology, antimicrobial susceptibility testing, bacterial, viral, fungal and parasitic infections, healthcare-associated infections, bloodstream infections, tuberculosis, and emerging and zoonotic pathogens. Studies applying One Health, genomics, next-generation sequencing and surveillance methods are particularly encouraged. Every submission undergoes double-blind peer review in line with COPE ethical principles. Accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) licence, with authors retaining copyright, and each receives a permanent Crossref DOI. Content is discoverable through Google Scholar and OpenAlex and harvestable via our OAI-PMH endpoint, ensuring citability and long-term availability for a global readership of researchers and practitioners.

Dedicated to the molecular, cellular, clinical and computational study of the immune system. It publishes original research, reviews, case reports and editorials spanning innate and adaptive immunity, autoimmunity and autoantibodies, tumor immunology and immunotherapy, infection and host defense, and the cytokine and chemokine networks that coordinate immune responses. The journal welcomes work on immune cell biology, neutrophil extracellular traps, antibody and receptor signaling, vaccine immunology, and inflammation, as well as studies in viral infection (including SARS-CoV-2 and post-COVID immunopathology), tuberculosis, and hepatitis. We encourage translational and methodological contributions, including immunology bioinformatics, Mendelian randomization of immune cell traits, and biomarker discovery using clinical and laboratory data. Intended for immunologists, clinician-scientists, oncologists, infectious-disease researchers and laboratory investigators worldwide, the journal bridges bench and bedside. Every submission undergoes double-blind peer review; accepted articles are published under a Creative Commons Attribution (CC-BY 4.0) licence with authors retaining copyright, assigned a permanent Crossref DOI, and made discoverable through OpenAlex, Google Scholar and an OAI-PMH endpoint. Editorial practice follows COPE principles.

Advances research across the full spectrum of autoimmunity and clinical immunology. The journal disseminates original scholarship on the breakdown of immune self-tolerance and the resulting systemic and organ-specific autoimmune diseases, serving immunologists, rheumatologists, clinical investigators, and translational scientists worldwide. We welcome work on systemic autoimmune rheumatic conditions such as systemic lupus erythematosus, rheumatoid arthritis, and Sjogren's syndrome, alongside organ-specific disorders including autoimmune thyroiditis, vitiligo, coeliac disease, and autoimmune skin disease. Mechanistic studies of epitope spreading, autoantibodies, innate and adaptive immunity, and molecular mimicry are central to our remit, as are investigations of environmental and infectious triggers, including COVID-19, Helicobacter pylori, and drug-induced autoimmunity. The journal also prioritizes diagnosis, classification, biomarkers, epidemiology, and therapeutics, from validation of SLICC and EULAR/ACR criteria to biologic and TNF-inhibitor strategies. We publish original research, systematic reviews, case reports, and editorials. Every submission undergoes double-blind peer review. Accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) licence with authors retaining copyright, receive a permanent Crossref DOI, and are made discoverable through OpenAlex, Google Scholar, and an OAI-PMH endpoint, in line with COPE ethical principles.

Advancing the science and clinical practice of infectious diseases. It publishes original research across infectious disease epidemiology, antimicrobial resistance and stewardship, emerging and re-emerging infections, tropical and neglected diseases, and healthcare-associated infections, serving clinicians, microbiologists, epidemiologists, and public health researchers worldwide. We welcome work across the spectrum of pathogens, including viral infections such as HIV/AIDS, hepatitis B, dengue, and Lassa fever; bacterial and fungal infections including sporotrichosis, leptospirosis, and scrub typhus; vaccine and immunization research; and clinical syndromes such as catheter-related bloodstream and post-surgical urinary tract infections. Studies on surveillance, diagnostics, antibiotic utilization (including WHO AWaRe classification), and One Health are especially encouraged. JOID accepts original research, systematic and narrative reviews, case reports, and editorials. Every submission undergoes double-blind peer review consistent with COPE principles. Accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) licence, with authors retaining copyright, and each receives a permanent Crossref DOI. Content is discoverable via OpenAlex and Google Scholar and harvestable through our OAI-PMH endpoint.

Advancing scholarship across vaccinology, immunization science, and vaccine-preventable disease control. The journal serves vaccinologists, immunologists, infectious disease researchers, public health scientists, clinicians, and veterinary researchers seeking a rigorous, internationally discoverable venue for original work. We welcome research on vaccine platforms and development (mRNA, viral vector, subunit, conjugate, and adjuvanted vaccines), vaccine immunology and correlates of protection, immunogenicity, safety and efficacy evaluation, and clinical and translational vaccine studies. The journal also covers vaccine-preventable disease epidemiology (including measles, cholera, tetanus, and COVID-19), immunization programs, vaccine hesitancy and awareness, global vaccine equity and distribution, therapeutic and anticancer vaccines, and One Health and veterinary vaccinology. We publish original research, systematic and narrative reviews, case reports, methods, and editorials. Every submission undergoes double-blind peer review; accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) licence with authors retaining copyright, and each receives a permanent Crossref DOI. Content is discoverable through OpenAlex and Google Scholar and is available for harvesting via our OAI-PMH endpoint, with editorial practice following COPE principles.

Dedicated to the study of viruses across human, animal, plant, and microbial systems. It publishes original research, reviews, case reports, and editorials in molecular and clinical virology, viral pathogenesis, host-virus interactions, antiviral therapeutics, and vaccine development. Core subject areas include antiviral drug resistance and HIV-1 reverse transcriptase mutations, broadly neutralizing antibodies and virus-like particle vaccines, emerging and zoonotic viruses such as monkeypox and other orthopoxviruses, plant and agricultural virology, and molecular viral diagnostics. It serves virologists, immunologists, infectious-disease clinicians, plant pathologists, vaccinologists, and diagnostic researchers seeking a rigorous, internationally accessible venue. Every submission undergoes double-blind peer review. Accepted articles are open access under a CC-BY 4.0 licence, with authors retaining copyright, and receive a permanent Crossref DOI. Content is discoverable via OpenAlex and Google Scholar and harvestable through OAI-PMH, and the journal follows COPE principles.

Devoted to the science and practice of allergy, asthma, and clinical immunology. It bridges laboratory immunology, translational science, and clinical care for allergists, immunologists, pulmonologists, dermatologists, pediatricians, and basic researchers worldwide. We welcome original research, systematic reviews, meta-analyses, clinical trials, case reports, and editorials across asthma and allergic rhinitis, food allergy and anaphylaxis, atopic dermatitis, chronic urticaria and angioedema, drug and venom hypersensitivity, and eosinophilic disorders. Particular emphasis falls on allergen-specific immunotherapy, type 2 inflammation, biologics and monoclonal antibody therapy, and immune tolerance. In clinical immunology the journal covers immunodeficiency, inborn errors of immunity, autoimmunity, mast cell disorders, and immune dysregulation, plus mechanistic work on IgE-mediated immunity, the microbiome and exposome, epithelial barrier dysfunction, and biomarkers such as basophil activation testing and serum tryptase. Every submission undergoes double-blind peer review. Accepted articles are open access under a CC-BY 4.0 licence with a permanent Crossref DOI, ensuring citability and discoverability through OpenAlex and Google Scholar.

Serves as a multidisciplinary forum for original scholarship on the structure, function, engineering, and clinical application of immunoglobulins, advancing knowledge across both basic immunology and translational antibody science. The journal welcomes work on monoclonal and polyclonal antibodies, therapeutic antibodies and antibody-drug conjugates, single-domain antibodies and nanobodies, bispecific and engineered formats, and the autoantibodies that drive autoimmune, renal, and transplant-related disease. Coverage extends to antibody discovery and engineering, immunoassay and ligand-binding-assay development, immunochemistry, antibody-mediated graft rejection (including HLA and non-HLA antibodies), and the validation, specificity, and reproducibility of research antibodies. We consider original research, reviews, methods papers, case reports, and editorials of interest to immunologists, biochemists, clinical and translational researchers, diagnostic laboratories, and biopharmaceutical scientists. Every submission undergoes double-blind peer review. Accepted articles are published under a Creative Commons Attribution (CC-BY 4.0) licence with authors retaining copyright, assigned a permanent Crossref DOI, and made discoverable through OpenAlex, Google Scholar, and our OAI-PMH endpoint. The journal follows COPE ethical principles.

Dedicated to the clinical, virological, immunological, and public-health dimensions of HIV and AIDS. It serves clinicians, virologists, immunologists, epidemiologists, public-health researchers, and policy specialists working to improve prevention, treatment, and the lives of people living with HIV. The journal welcomes original research, reviews, clinical trials, case reports, and editorials across antiretroviral therapy (ART) and drug resistance, viral load and CD4 monitoring, HIV prevention including PrEP, PEP and vaccines, and prevention of mother-to-child transmission. We also prioritize work on opportunistic infections, tuberculosis and hepatitis co-infections, the latent HIV reservoir, and HIV cure research. Further themes include HIV epidemiology and surveillance, care of immunocompromised patients, immune reconstitution, treatment adherence, key-population health, and the lived experience of HIV/AIDS care across diverse settings. Every submission undergoes double-blind peer review. Accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) licence with authors retaining copyright, are assigned a permanent Crossref DOI, and are discoverable through OpenAlex, Google Scholar, and an OAI-PMH endpoint, following COPE ethical principles.

Dedicated to the study of fungi, fungus-like organisms and lichens across the whole tree of life. The journal serves mycologists, microbiologists, plant pathologists, clinicians and biotechnologists by publishing rigorous original research, taxonomic treatments and critical reviews that advance our understanding of fungal diversity, biology and impact. We welcome submissions in fungal taxonomy and systematics (including formally described new species, phylogenetics and ITS barcoding of Ascomycota and Basidiomycota), medical and clinical mycology (invasive aspergillosis, candidiasis, cryptococcosis, dermatophytes and antifungal resistance), fungal ecology and biodiversity (mycorrhizal symbioses, wood-decay fungi and conservation), and fungal genetics, genomics, secondary metabolites and biotechnology, alongside plant-pathogenic and agricultural mycology. Article types include original research, reviews, taxonomic and nomenclatural papers, short communications, case reports and editorials. Every manuscript undergoes double-blind peer review and follows COPE ethical principles. Accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) licence, with authors retaining copyright, and each receives a permanent Crossref DOI. Content is discoverable through Google Scholar and OpenAlex and exposed via an OAI-PMH endpoint to ensure citability and long-term preservation of the mycological record.